- Home
- ACRS vs LESL Comparison
ACRS vs LESL Comparison
Compare ACRS & LESL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- LESL
- Stock Information
- Founded
- ACRS 2012
- LESL 1963
- Country
- ACRS United States
- LESL United States
- Employees
- ACRS N/A
- LESL N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- LESL Diversified Commercial Services
- Sector
- ACRS Health Care
- LESL Miscellaneous
- Exchange
- ACRS Nasdaq
- LESL Nasdaq
- Market Cap
- ACRS 127.6M
- LESL 116.5M
- IPO Year
- ACRS 2015
- LESL 2020
- Fundamental
- Price
- ACRS $1.26
- LESL $0.73
- Analyst Decision
- ACRS Strong Buy
- LESL Hold
- Analyst Count
- ACRS 7
- LESL 11
- Target Price
- ACRS $10.67
- LESL $2.32
- AVG Volume (30 Days)
- ACRS 801.8K
- LESL 2.3M
- Earning Date
- ACRS 05-08-2025
- LESL 05-08-2025
- Dividend Yield
- ACRS N/A
- LESL N/A
- EPS Growth
- ACRS N/A
- LESL N/A
- EPS
- ACRS N/A
- LESL N/A
- Revenue
- ACRS $17,777,000.00
- LESL $1,319,859,000.00
- Revenue This Year
- ACRS N/A
- LESL $2.77
- Revenue Next Year
- ACRS $425.96
- LESL $2.93
- P/E Ratio
- ACRS N/A
- LESL N/A
- Revenue Growth
- ACRS N/A
- LESL N/A
- 52 Week Low
- ACRS $0.95
- LESL $0.51
- 52 Week High
- ACRS $5.17
- LESL $6.02
- Technical
- Relative Strength Index (RSI)
- ACRS 43.64
- LESL 56.70
- Support Level
- ACRS $1.20
- LESL $0.64
- Resistance Level
- ACRS $1.46
- LESL $0.73
- Average True Range (ATR)
- ACRS 0.11
- LESL 0.05
- MACD
- ACRS 0.02
- LESL 0.03
- Stochastic Oscillator
- ACRS 41.77
- LESL 94.11
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About LESL Leslie's Inc.
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products across chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company offers its products and services for Residential Pool, Residential Spa, Professional Pool, and Commercial Pool consumers. Geographically, it operates only in the United States.